These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24096112)

  • 1. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
    Lademann J; Martschick A; Kluschke F; Richter H; Fluhr JW; Patzelt A; Jung S; Chekerov R; Darvin ME; Haas N; Sterry W; Zastrow L; Sehouli J
    Skin Pharmacol Physiol; 2014; 27(2):66-70. PubMed ID: 23969763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
    Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
    Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Molpus KL; Anderson LB; Craig CL; Puleo JG
    Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
    Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
    Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
    Sehouli J; Oskay-Ozcelik G; Kühne J; Stengel D; Hindenburg HJ; Klare P; Heinrich G; Schmalfeldt B; Mertens H; Camara O; Lichtenegger W;
    Ann Oncol; 2006 Jun; 17(6):957-61. PubMed ID: 16600975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of overall survival with 40 and 50mg/m
    Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
    Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
    Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
    Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
    Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.